QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company's product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products. The company was founded in 1979 and is headquartered in San Diego, California.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on QDEL shares. UBS Group started coverage on shares of QuidelOrtho in a research report on Wednesday, July 20th. They set a "sell" rating and a $86.00 target price for the company. StockNews.com cut QuidelOrtho from a "buy" rating to a "hold" rating in a report on Monday. Finally, JPMorgan Chase & Co. initiated coverage on QuidelOrtho in a report on Friday, June 17th. They set a "neutral" rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $98.67.
QuidelOrtho Stock Down 1.9 %
Shares of QDEL traded down $1.67 during trading hours on Friday, reaching $86.07. The stock had a trading volume of 13,463 shares, compared to its average volume of 783,452. QuidelOrtho has a 12 month low of $83.39 and a 12 month high of $180.06. The firm has a 50-day simple moving average of $98.50 and a 200 day simple moving average of $101.54. The company has a current ratio of 1.73, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $5.76 billion, a price-to-earnings ratio of 3.64 and a beta of 0.03.